Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NGL Fine-ChemNSE:NGLFINE +3.96%79 EV-to-EBIT is 24.32 as of Aug. 19, 2026, which is 40% above its 10-year median of 17.39. GuruFocus rates NSE:NGLFINE with a GF Score™ of 79/100 and a GF Value™ of ₹3,023.07 (Fairly Valued). The stock has 4 warning signs investors should review. Among 684 Drug Manufacturers companies, NGL Fine-Chem ranks worse than 72.81% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
NGL Fine-Chem's Enterprise Value for the quarter that ended in Jun. 2026 was ₹19,198 Mil.
NGL Fine-Chem's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹802 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGL Fine-Chem EV-to-EBIT Related Terms
NGL Fine-Chem EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's EV-to-EBIT falls into.
NGL Fine-Chem's current Enterprise Value is ₹19,490 Mil.
NGL Fine-Chem's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹802 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGL Fine-Chem (NSE:NGLFINE) has a EV-to-EBIT of 24.32 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NGL Fine-Chem and its competitors. This is 40% above median its historical median of 17.39. Over the past decade, NGL Fine-Chem's EV-to-EBIT has ranged from 6.60 to 38.05. According to the industry distribution chart, NGL Fine-Chem ranks #498 out of 684 companies in the Drug Manufacturers industry, placing it in the top 72.8%.
Is NGL Fine-Chem's EV-to-EBIT too high?
NGL Fine-Chem's current EV-to-EBIT of 24.32 is 40% above median its 10-year median of 17.39. Over the past 10 years, this metric has ranged from a low of 6.60 to a high of 38.05. The Drug Manufacturers industry median EV-to-EBIT is 15.69. NGL Fine-Chem's value of 24.32 is 55.1% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #498 out of 684 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #498 out of 684 companies for EV-to-EBIT. This places NGL Fine-Chem in the lower half of its industry. The industry median EV-to-EBIT is 15.69. NGL Fine-Chem's value of 24.32 is 55.1% above this benchmark. Historically, NGL Fine-Chem's own EV-to-EBIT has ranged from 6.60 to 38.05 over the past decade. While the company's 10-year median is 17.39 vs. the industry median of 15.69, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.69, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current EV-to-EBIT of 24.32 is 55.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current EV-to-EBIT is 24.32, which is 40% above median its own 10-year median of 17.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,023.07, compared to a current price of ₹3,023.50 — trading 0% above its estimated fair value. The current EV-to-EBIT is 24.32, which is 40% above median its 10-year median of 17.39 and 55.1% above the Drug Manufacturers industry median of 15.69. NGL Fine-Chem's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current EV-to-EBIT is 24.32 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,023.50 is trading 0% above its estimated GF Value™ of ₹3,023.07.
GuruFocus considers NGL Fine-Chem to be Fairly Valued.
Key valuation signals for NSE:NGLFINE:
EV-to-EBIT: 24.32 (40% above median its 10-year median of 17.39)
GF Value™: ₹3,023.07 vs. price of ₹3,023.50 (0% above fair value)
Industry Position: 55.1% above the Drug Manufacturers median (#498 of 684)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
79GF Score
Get the complete analysis for NSE:NGLFINE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
